Eligible trials included those evaluating IL-17 or IL-23 inhibitors for PsO and documented PASI scores. Interleukin-17 (IL-17) inhibitors demonstrated faster psoriasis (PsO) clearance than Interleukin ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Although TNF inhibitors remain the first choice biologic ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE registry ...

IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily pretreated patients with active disease is not well known. This registry study ...

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 were associated with a lower rate of serious infection among older adults with psoriatic disease. These biologics may have important safety ...

This retrospective cohort study analysed the effectiveness and survival of patients with psoriasis undergoing therapeutic biologic dose spacing of secukinumab or brodalumab. The analysis included 80 ...

Guselkumab and risankizumab demonstrated the highest adjusted survival time for effectiveness (RMST, 1.93 years for both; 95% CI, 1.91-1.95 and 1.90-1.96 years, respectively). Risankizumab showed the ...

Sanofi SA has synthesized interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of psoriasis, rheumatoid arthritis, radiographic ...

Anew Therapeutics Pte Ltd. has synthesized heterocyclic compounds acting as interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors. As such, they are reported to be useful ...

Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn't respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should ...